13F Holdings
中文EN

MRKR Marker Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1094038 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-30.7%
TTM net income YoY14.8%
TTM EPS YoY58.3%
Revenue 3-yr CAGR1.4%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-365.9%
Net margin-275.9%
FCF margin—
EBITDA margin—

Returns

ROE-77.0%
ROA-63.3%
ROIC (approx.)—
Asset turnover0.23x

Leverage & solvency

Liabilities / assets20.9%
Debt / equity0.00x
Current ratio4.79x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-17.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$3.55M$6.59M$3.31M$3.51M$1.24M
R&D expense$11.80M$13.47M$10.42M$11.97M$27.79M
SG&A expense$4.18M$4.24M$7.48M$11.34M$12.92M
Operating income-$12.89M-$11.12M-$14.58M-$19.79M-$39.48M
Pretax income-$12.18M-$10.68M-$14.04M-$19.78M—
Income tax-$15,156$49,953$3,675——
Net income-$12.16M-$10.73M-$8.24M-$29.93M-$41.88M
EBITDA———-$17.00M-$37.33M
EPS (basic)-0.79-1.19-0.94-3.58-5.47
EPS (diluted)-0.79-1.19-0.94-3.58-5.47
Weighted avg. shares (diluted)15.31M8.98M8.81M8.35M7.65M
Balance sheet
Cash & equivalents$16.07M$19.19M$15.11M$11.78M$43.50M
Current assets$19.07M$22.02M$17.13M$16.62M$45.98M
PP&E, net———$12.32M$12.32M
Total assets$19.07M$22.02M$17.13M$34.42M$68.14M
Current liabilities$2.27M$3.46M$3.07M$7.78M$12.90M
Total liabilities$2.27M$3.46M$3.07M$14.82M$24.15M
Shareholders' equity$16.80M$18.56M$14.05M$19.60M$43.99M
Shares outstanding16.70M10.70M8.90M8.40M8.30M
Cash flow statement
Operating cash flow-$12.01M-$10.91M-$16.44M-$26.97M-$27.28M
Investing cash flow——$18.66M-$4.95M-$3.13M
Financing cash flow$9.86M$14.99M$1.11M$202,130$52.56M
Depreciation & amortization———$2.79M$2.15M
Stock-based compensation$537,540$245,864$858,269$3.30M$5.96M

Free plan shows the latest 5 periods; Pro shows all 26 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.